Supplementary Table 1. Absolute CIN3+ risks for single and combined triage tests within the VUSA-Screen trial and POBASCAM trial separately

Test result	N	CIN3+ (n)	Absolute CIN3+ risk	95% CI
VUSA-Screen study	123	28	22.8%	(15.4 - 30.2%)
Single triage tests				_
Methylation +	47	19	40.4%	(26.4 - 54.5%)
Methylation -	76	9	11.8%	(4.6 - 19.1%)
HPV16/18 +	50	17	34.0%	(20.9 - 47.1%)
HPV16/18 -	73	11	15.1%	(6.9 - 23.3%)
HPV 16/18/31/33/45 +	75	23	30.7%	(20.2 - 41.1%)
HPV 16/18/31/33/45 -	48	5	10.4%	(1.8 - 19.0%)
Combined triage tests				
HPV16/18 + and methylation +	24	11	45.8%	(25.9 - 65.8%)
HPV16/18 + and methylation -	26	6	23.1%	(6.9 - 39.3%)
HPV16/18 - and methylation +	23	8	34.8%	(15.3 - 54.2%)
HPV16/18 - and methylation -	50	3	6.0%	(0 - 12.6%)
HPV16/18/31/33/45 + and methylation +	33	15	45.5%	(28.5 - 62.4%)
HPV16/18/31/33/45 + and methylation -	42	8	19.0%	(7.2 - 30.9%)
HPV16/18/31/33/45 - and methylation +	14	4	28.6%	(4.9 - 52.2%)
HPV16/18/31/33/45 - and methylation -	34	1	2.9%	(0 - 8.6%)
POBASCAM study	171	29	17.0%	(11.3 - 22.6%)
Single triage tests				
Methylation +	74	21	28.4%	(18.1 - 38.7%)
Methylation -	97	8	8.2%	(2.8 - 13.7%)
HPV16/18 +	77	18	23.4%	(13.9 - 32.8%)
HPV16/18 -	94	11	11.7%	(5.2 - 18.2%)
HPV 16/18/31/33/45 +	120	25	20.8%	(13.6 - 28.1%)
HPV 16/18/31/33/45 -	51	4	7.8%	(0.5 - 15.2%)
Combined triage tests				
HPV16/18 + and methylation +	38	14	36.8%	(21.5 - 52.2%)
HPV16/18 + and methylation -	39	4	10.3%	(0.7 - 19.8%)
HPV16/18 - and methylation +	36	7	19.4%	(6.5 - 32.4%)
HPV16/18 - and methylation -	58	4	6.9%	(0.4 - 13.4%)
HPV16/18/31/33/45 + and methylation +	61	18	29.5%	(18.1 - 41.0%)
HPV16/18/31/33/45 + and methylation -	59	7	11.9%	(3.6 - 20.1%)
HPV16/18/31/33/45 - and methylation +	13	3	23.1%	(0.2 - 46.0%)
HPV16/18/31/33/45 - and methylation -	38	1	2.6%	(0 - 7.7%)

Abbreviations: N, group total; n, number of CIN3+ detected; CIN3+, cervical intraepithelial neoplasia grade 3 or worse; 95% CI, 95% confidence interval; +, positive; -, negative